449 related articles for article (PubMed ID: 29791768)
1. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
2. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
3. A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
Seya T; Takeda Y; Matsumoto M
Adv Drug Deliv Rev; 2019 Jul; 147():37-43. PubMed ID: 31302192
[TBL] [Abstract][Full Text] [Related]
4. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy.
Matsumoto M; Takeda Y; Seya T
Expert Opin Biol Ther; 2020 Aug; 20(8):937-946. PubMed ID: 32223572
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
[TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.
Matsumoto M; Takeda Y; Tatematsu M; Seya T
Front Immunol; 2017; 8():1897. PubMed ID: 29312355
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.
Babikr F; Wan J; Xu A; Wu Z; Ahmed S; Freywald A; Chibbar R; Wu Y; Moser M; Groot G; Zhang W; Zhang B; Xiang J
Cell Mol Immunol; 2021 Dec; 18(12):2632-2647. PubMed ID: 34782757
[TBL] [Abstract][Full Text] [Related]
8. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
9. Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.
Takeda Y; Takaki H; Fukui-Miyazaki A; Yoshida S; Matsumoto M; Seya T
Biochem Biophys Res Commun; 2018 Dec; 506(4):1019-1025. PubMed ID: 30404733
[TBL] [Abstract][Full Text] [Related]
10. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
11. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
13. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Karyampudi L; Lamichhane P; Scheid AD; Kalli KR; Shreeder B; Krempski JW; Behrens MD; Knutson KL
Cancer Res; 2014 Jun; 74(11):2974-85. PubMed ID: 24728077
[TBL] [Abstract][Full Text] [Related]
15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
17. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
19. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a
Takeda Y; Azuma M; Funami K; Shime H; Matsumoto M; Seya T
Front Immunol; 2018; 9():496. PubMed ID: 29593736
[No Abstract] [Full Text] [Related]
20. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]